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Abstract
Insulin-like growth factor-I (IGF-I) is produced mainly in the liver and it induces beneficial effects on the nutritional
status, the liver function and oxidative hepatic damage in cirrhotic rats. The aim of this work was to analyze the effect of
IGF-I on mechanisms of fibrogenesis in cirrhotic rats. Liver cirrhosis was induced by CCl4 inhalation and phenobarbital in
Wistar rats. Ten days after stopping CCl4 administration (day 0), rats received either IGF-I (2 Wg/100 g bw/day) (CI+IGF) or
saline (CI) subcutaneously during 14 days. Animals were sacrificed on day 15. As control groups were used: healthy rats
(CO) and healthy rats treated with IGF-I (CO+IGF). Liver histopathology, hydroxyproline content, prolyl hydroxylase
activity, collagen I and III mRNA expression and the evolution of transformed Ito cells into myofibroblasts were assessed.
Among the two control groups (CO+IGF), no differences were found in hydroxyproline content and these levels were lower
than those found in the two cirrhotic groups. Compared with untreated cirrhotic rats, the CI+IGF-I animals showed a
significant reduction in hydroxyproline content, prolyl hydroxylase activity and collagen K1(I) and K1(III) mRNA
expression. A higher number of transformed Ito cells (K-actin +) was observed in untreated cirrhotic animals as compared to
CO and CI+IGF groups. In summary, treatment with IGF-I reduced all of the studied parameters of fibrogenesis. In
conclusion, low doses of IGF-I induce in vivo an antifibrogenic effect in cirrhotic rats. ß 2001 Elsevier Science B.V. All
rights reserved.
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1. Introduction
Cellular damage and regeneration with ¢brogene-
sis are processes involved in the development of liver
cirrhosis [1,2]. Liver ¢brosis is characterized by a
marked accumulation of extracellular material, espe-
cially interstitial collagen (types I and III) [3], and
this process is a result of increased collagen synthesis
[3,4]. Collagen synthesis depends on mRNA expres-
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sion as well as the enzymatic activities such as prolyl
hydroxylase (EC 1.14.11.2; proline 2-oxoglutarate di-
oxygenase) [5,6]. On the other hand, it is known that
Ito cells transformed into myo¢broblast are the most
important cellular source of hepatic ¢brosis [6].
Insulin-like growth factor-I (IGF-I) is a growth
factor with anabolic e¡ects [7], which is mainly pro-
duced by hepatocytes. Patients with advanced liver
cirrhosis show low serum concentrations of this hor-
mone [8^12]. Previous works have shown bene¢cial
e¡ects of low doses of IGF-I on experimental cirrho-
sis (nutritional status [13], malabsorption [14^16], os-
teopenia [17] and hypogonadism [18]) including liver
function tests and oxidative liver damage [19]. This
growth factor has been considered a potential factor
involved in ¢brogenesis both in vitro and in vivo [20^
26]. The reported role for IGF-I as stimulator of Ito
cell proliferation in vitro and the observation of in-
creased expression of IGF receptors during the pro-
cess of ¢brogenesis support this opinion [20^26].
We have previously shown that the administration
of low doses of IGF-I to CCl4-cirrhotic rats im-
proves liver function and reduces ¢brosis [19]. To
gain more insight into the mechanisms behind the
hepatoprotective e¡ects of IGF-I, we have explored
the e¡ect of this treatment on mechanisms leading to
¢brosis. Hence, histopathology, evaluation of trans-
formed Ito cells into myo¢broblasts, hydroxyproline
content, prolyl hydroxylase activity and collagen
types I and III mRNA expression were assessed.
2. Materials and methods
2.1. Induction of liver cirrhosis
All the experimental procedures were performed in
conformity with the Guide for the Care and Use of
Laboratory Animals (7th edn., National Academy
Press, Washington, DC). Forty-eight male Wistar
rats (3 weeks old, weighing about 130^150 g) were
used for this study. Twenty-four of them were ran-
domly allocated to two control groups. Liver cirrho-
sis was induced in the remaining 24 rats by inhala-
tion of CCl4 (Merck, Darmstadt, Germany). The
organic solvent was administered twice a week,
with a progressively increasing exposure time, rang-
ing from 1 to 5 min, during an 11 week period as
previously described [14,19]. To accelerate the devel-
opment of cirrhosis, phenobarbital (Luminal, Bayer,
Leverkusen, Germany) was added to drinking water
(400 mg/l) beginning 1 week before the ¢rst CCl4
exposure and throughout the entire period of cirrho-
sis induction [27]. Animals were housed in cages
placed in a room with a 12 h light^darkness cycle
and constant humidity and temperature (20‡C).
Both food (standard semipuri¢ed diet for rodents,
purchased from B.K. Universal, Sant Vicent dels
Horts, Spain) and water were given ad libitum.
Healthy control rats (CO) were subjected to the
same protocol excluding phenobarbital administra-
tion and CCl4 exposure.
2.2. Study design
Ten days after stopping CCl4 administration, the
study period was initiated. Rats were randomly as-
signed to receive either vehicle (saline) (group CI,
n = 12) or recombinant human (rh) IGF-I (2 Wg
IGF-I/100 g bw/day, in two divided doses) (group
CI+IGF, n = 11) subcutaneously for 14 days. Healthy
rats were also randomly assigned to receive vehicle
(CO, n = 12) or IGF-I (CO+IGF-I, n = 12) at the
same dosage as the CI+IGF group.
Animals were sacri¢ced by decapitation 24 h after
administering the last dose. Livers were dissected
out. Tissue sample from the left major liver lobe
was processed (¢xed in Bouin solution) for histolog-
ical examination. Tissue specimens were immediately
frozen by immersion in liquid N2 and stored at
380‡C.
The inclusion criteria for the study were estab-
lished cirrhosis with ¢brous septa delimiting regener-
ative nodules. None of the cirrhotic rats in this series
had ascites.
2.3. Histological degree of ¢brosis and hydroxyproline
content
In liver sections stained with Masson’s trichrome,
semiquantitative assessment of ¢brosis was blindly
performed using a numerical scoring system based
on the number, length and thickness of ¢brous septa
as previously described [19] that explored the whole
preparation. The length of the septa (examined at
80U magni¢cation) was assessed as follows: 1 point,
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minimal grade ¢brosis that can be observed in nor-
mal livers; 4 points, septa con£uent between portal
tracts and between portal tracts and central veins;
and 2 or 3 points, intermediate lengths of septa ob-
served. The width of the ¢brous septa was calculated
at 150U magni¢cation, scoring 4 points when the
mean value of the thickness of nine septa (three peri-
portal, three perivenous and three perinodular) was
75^55 Wm, 3 points when it was 55^40 Wm and
2 points when it was approx. 40^30 Wm. The number
of septa was scored as 4 points when there were
numerous septa extending into the nodules, thus dis-
secting a small number of hepatocytes forming mi-
cronodules, 2^3 points when septa penetrating into
nodules were less numerous surrounding bigger nod-
ules, and 1 point when there was no formation of
micronodules inside macronodules. Each preparation
(four ¢elds, at magnifying lens) was evaluated by two
di¡erent observers, receiving a maximum of 12
points each time. The arithmetic mean of the two
scores was taken as the ¢nal score.
Liver hydroxyproline levels were determined as a
rough index of collagen content by multiplying the
hydroxyproline content by the factor 7.46 [28].
Brie£y, 50 mg aliquots of liver tissue were hydrolyzed
for 22 h at 110‡C in 6 N HCl, and hydroxyproline
content was quanti¢ed by HPLC using the Pico-Tag
method (Waters, Milford, MA, USA) for amino acid
analysis (coe⁄cient inter- and intraassay varia-
tion = 1% and 0.05% respectively; detection limits
6 40 pmol). Hydrolysate, 25 Wl, was derivatized
with phenyl isothiocyanate at pH 9^10 to produce
phenyl thiocarbamyl amino acid derivatives. After
derivatization, samples were dried under vacuum
and redissolved with 0.01 M disodium hydrogen
phosphate in acetonitrile (pH 7.4). Finally, samples
were introduced into a 300U3.9 mm HPLC chroma-
tographic column (Waters), with a 10 Wm particle
stationary phase, at 46‡C. An automatic injection
system was used to introduce samples in the column.
As a mobile phase, 70 mM sodium acetate in aceto-
nitrile/methyl alcohol/water (45:45:10) pH 6.46 was
used. Commercially available standard amino acid
solutions were processed similarly, and used as exter-
nal standard to calculate hydroxyproline concentra-
tions in the experimental samples.
Hydroxyproline content was expressed as Wmol/mg
liver protein. Liver protein concentration was deter-
mined in liver tissue homogenates by Bradford’s
method [29].
2.4. Enzymatic activity of prolyl hydroxylase
Prolyl hydroxylase was measured in liver homoge-
nates by the method of Hutton et al. [30] with slight
modi¢cations as described previously [31]. This
method measures the tritiated water formed when
tritiated proline (40 Ci/mmol, New England Nuclear,
Boston, MA, USA) present in a 3,4 (n) proline-la-
beled polypeptide substrate is hydroxylated to hy-
droxyproline. Brie£y, this technique involves the ho-
mogenization of the frozen liver sample in a solution
of sucrose 0.25 M, EDTA 10 WM, dithiothreitol
1 mM, 50 Wg/ml phenylmethylsulfonyl £uoride,
0.1% (w/v) Triton X-100, and 50 mM Tris^HCl bu¡-
er (pH 7.2) a 4‡C, in an Elvehjem^Potter apparatus.
The incubation was carried out with 200 Wl of the
aliquots of the supernatants that were centrifuged at
500Ug for 5 min, 150 Wl [3H]proline-labeled sub-
strate prepared in isolated chick embryo connective
tissue and 800 Wl Tris^HCl bu¡er (pH 7.2), contain-
ing 1 mM ferrous ammonium sulfate, 2 g/l denatu-
ralized bovine serum albumin, 0.4 g/l catalase
(2U106 u/l), 2 mM K-ketoglutarate, 0.1 mM dithio-
threitol, and 50 mM ascorbic acid. The reaction was
incubated aerobically for 30 min at 30‡C and
stopped with 100 Wl of 50% trichloroacetic acid.
The tritiated water produced was separated by vac-
uum distillation and counted in a scintillation coun-
ter. A blank obtained by the addition of homogeni-
zation bu¡er instead of sample was used in each
determination. Prolyl hydroxylase activity in each
homogenate and blank was measured in duplicate.
Total protein concentrations in homogenates were
measured by the method of Bradford [29]. The re-
sults were expressed as cpm/mg protein.
2.5. RNA extraction and hybridization
RNA extraction was performed by homogeniza-
tion in 4 M guanidinium thiocyanate followed by
phenol chloroform extraction. The RNA was spec-
trophotometrically measured and 25 Wg/lane were
then analyzed by formaldehyde agarose electropho-
resis and transferred by capillary blotting to nylon
¢lters (Gene Screen, New England Nuclear). Ethid-
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ium bromide staining was used to assess the relative
amount and the intact nature of the RNA. Subse-
quent probing of the Northern blot hybridizations
was performed using cDNAs 32P-labeled by random
priming using a commercially available kit (Amer-
sham, UK). The cDNAs used include GADPH as
an internal control, K1(I) collagen and K1(III) colla-
gen. Nylon membranes were prehybridized and hy-
bridized at 42‡C in 50% formamide containing
6USSC, 50 mM sodium phosphate pH 7.0, 1 mM
EDTA, 1UDenhardt’s solution, 50 Wg/ml sheared
single-stranded salmon sperm DNA, and 10% dex-
tran sulfate. Prehybridization was performed for 4 h
and hybridization for 16 h in the presence of 1U106
cpm/ml cDNA. All the blots were washed under
stringent conditions at 65‡C. Autoradiograms were
developed using Kodak XAR-5 ¢lm and intensifying
screens at 380‡C. After each hybridization step, the
blot was washed with 50% formamide in 1USSC at
75‡C for 45 min to remove the probe.
Quanti¢cation was performed on scanned X-ray
¢lms of Northern blots corrected by GADPH
mRNA in the same RNA preparations.
2.5.1. Immunostaining for K-actin
When injured, liver Ito cells assume a ¢broblast-
like morphology expressing K-actin. These trans-
formed cells produce large amounts of collagen. Im-
munohistochemical staining of K-actin in para⁄n
sections (4 Wm) was performed using an avidin^bio-
tin peroxidase technique as described by Shu el al.
[32] with a few modi¢cations. The primary antibody
anti-K-actin was obtained from Bio Genex Labora-
tories (San Roman, USA). Negative controls were
performed by omission of the antigen retrieval pro-
cedure. The positive staining was estimated blindly in
the entire preparation using a numerical score from
1 to 4 points as follow: 1 point, staining exclusively
localized in smooth muscle, around the vessels that
can be observed in normal livers; 4 points, large lines
of immunostaining along the ¢brous septa; 2 or
3 points, little stain deposition or intermediate
lengths of lines, respectively.
2.6. Statistical analysis
Data are expressed as mean ( þ S.E.M.). To assess
Fig. 1. Histopathologic ¢ndings in liver biopsy (4 Wm section; Masson’s trichrome stain; original magni¢cation 150U) from: CI, un-
treated cirrhotic rat; CI+IGF, cirrhotic rat treated with IGF-I. Liver hydroxyproline content in these two animals was 4.71 and 3.66
Wg/mg protein for CI and CI+IGF, respectively.
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the homogeneity among the di¡erent groups of rats a
Kruskal^Wallis test was used, followed by multiple
post-hoc comparisons using Mann^Whitney U tests
with Bonferroni adjustment. A regression model was
¢tted considering malondialdehyde (MDA) concen-
tration and prolyl hydroxylase activity as the depen-
dent and independent variables, respectively. Any
P value less than 0.05 was considered to be statisti-
cally signi¢cant. Calculations were performed with
SPSSW in v.6.0. program.
3. Results
3.1. Liver histology and liver hydroxyproline content
All rats from groups CI and CI+IGF showed, at
the end of the study, micronodular or macromicro-
nodular cirrhosis. The histological score of ¢brosis
was signi¢cantly lower in CI+IGF than in CI
(9.1 þ 0.5 vs. 10.4 þ 0.2; P6 0.05) (Fig. 1). In accor-
dance with this observation, hydroxyproline content
(Wmol/mg protein) was also signi¢cantly lower in hy-
droxyproline cirrhotic rats treated with IGF-I than
in CI animals (3.2 þ 0.3 vs. 3.8 þ 0.3, P6 0.05) and
signi¢cantly higher in these two groups than in
healthy controls (0.7 þ 0.1, P6 0.01, both) (Fig. 2A).
Similar values were found for the two control
groups (CO+IGF = 0.69 þ 0.06 Wmol hydroxypro-
line/mg protein). Accordingly, no histopathological
¢ndings were observed in the CO+IGF group.
Therefore, no further mechanisms leading to ¢brosis
were studied in this group.
3.2. Prolyl hydroxylase activity
High hepatic levels of prolyl hydroxylase activity
(cpm/mg protein) were observed in CI rats as com-
pared with controls (CI = 76.75 þ 5.75; CO = 32.73 þ
2.22; P6 0.01). However, this enzymatic activity was
signi¢cantly reduced in CI+IGF as compared with
untreated cirrhotic rats (CI+IGF = 66.76 þ 6.38;
P6 0.05) (Fig. 2B).
3.3. Expression of mRNAs coding for type I and III
collagens
The expression of mRNAs coding for K1(I) and
K1(III) chain collagens was investigated by Northern
blot. The absorbance values scanned from X-ray
¢lms of Northern blots were corrected for GADPH
mRNA used as blot control (collagen K1(I): CO =
2.20 þ 0.43; CI = 5.87 þ 1.10; CI+IGF = 3.75 þ 0.53,
P6 0.01 CO vs. cirrhotic groups, and P6 0.05 CI
vs. CI+IGF group; and collagen K1(III) CO =
5.51 þ 1.02; CI = 33.93 þ 5.54; CI+IGF = 24.50 þ 4.93,
Fig. 2. (A) Liver hydroxyproline content, in the three main ex-
perimental groups: CO, healthy controls; CI, untreated cir-
rhotic group; CI+IGF, cirrhotic animals treated with IGF-I.
(B) Activity of prolyl hydroxylase (cpm/mg protein) in the three
groups. Hepatic levels of prolyl hydroxylase activity were higher
in untreated cirrhotic rats (CI) that in controls (CO) (P6 0.01).
This enzymatic activity was signi¢cantly reduced in cirrhotic an-
imals treated with IGF-I (CI+IGF) as compared with CI
(P6 0.05). *P6 0.05, **P6 0.01, ***P6 0.001.
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P6 0.01 CO vs. cirrhotic groups, and P6 0.05 CI vs.
CI+IGF animals). As shown in Figs. 3 and 4, there
were di¡erences in the expression of K1(I) and
K1(III) collagens in both cirrhotic groups as com-
pared to the CO group. However, the expression of
these mRNAs was lower in the CI+IGF-I group
than in the CI group. The same ¢lters were succes-
sively hybridized with K1(I) and K1(III) collagen
cDNA. Thus, the values are not directly comparable.
3.4. Immunohistochemistry for K-actin
The hepatic distribution of K-actin, as a marker of
myo¢broblasts, was performed using immunohisto-
chemistry, because myo¢broblasts are considered
the most important source of collagen [6,33,34]. In
liver sections from all CO animals, K-actin immuno-
staining was localized exclusively in myocytes, sur-
rounding the vessels (Fig. 5, CO, score: 1.0 þ 0.0).
In the livers from the CI group immunostaining
was also found in the ¢brous septa and in many
instances these were con£uent (between portal tracts
and around the central veins), and the immunostain-
ing was as strong as in myocyte cells (Fig. 5, CI,
score: 2.7 þ 0.3 points). However, K-actin immuno-
staining was much lower in the CI+IGF than in
the CI group (Fig. 5, CI+IGF, score: 2.1 þ 0.2).
Semiquantitative scoring for K-actin showed signi¢-
cant di¡erences between controls and cirrhotic
groups (P6 0.001) and between untreated and
IGF-treated rats (P6 0.05).
3.5. Lipid peroxidation index: correlation between
malondialdehyde and prolyl hydroxylase activity
In order to ¢nd a relationship between parameters
of ¢brogenesis and oxidative liver damage, MDA, an
index of lipid peroxidation [35,36], was assessed as
described in a previous work [19]. Hepatic levels of
MDA (nmol/g tissue) were increased in CI rats as
compared with the control group (CI = 158 þ 35;
CO = 40 þ 3; P6 0.01) and as was previously re-
ported in a similar protocol [19], this marker of lipid
peroxidation was again signi¢cantly reduced in
CI+IGF as compared with CI (CI+IGF = 57 þ 6
nmol/g tissue, P6 0.01). A signi¢cant and direct cor-
relation between hepatic MDA and prolyl hydroxy-
lase activity was found (r = 0.57, P6 0.01).
Fig. 3. Northern blot analysis : levels of collagen K1(I) mRNA in liver from healthy controls (CO, n = 12), untreated cirrhotic rats (CI,
n = 12) and the cirrhotic group treated with IGF-I (CI+IGF, n = 11). Expression of collagen K1(I) was 2.67-fold higher in the CI
group than in the CO group, and 1.70-fold in CI+IGF animals. *P6 0.05, **P6 0.01.
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4. Discussion
This study shows that several mechanisms leading
to ¢brogenesis in rats with CCl4-induced cirrhosis are
reduced with low doses of IGF-I over a 2 week peri-
od. These mechanisms, such as prolyl hydroxylase
activity, transformation of Ito cells into myo¢bro-
blasts and mRNA expression of the most abundant
types (K1(I) and K1(III)) of collagen, appear to be
relevant in the development of ¢brosis in the liver. In
fact, the histopathological scores of ¢brosis and hy-
droxyproline content were lower in cirrhotic rats
treated with IGF-I than in untreated cirrhotic ani-
mals.
In a previous protocol, we reported similar histo-
logical ¢ndings [19]. The above mentioned work sug-
gested hepatoprotective e¡ects on the liver in cir-
rhotic rats which received a short-term course of
IGF-I. We observed a decrease in lipid peroxidation
associated with an increase of antioxidant enzyme
activities in hepatic tissue [19]. Interestingly enough,
the present study demonstrates that IGF-I not only
decreases hepatic collagen content as was previously
shown [19], but also its synthesis, reducing both prol-
yl hydroxylase activity and collagen mRNA expres-
sion.
Although the mechanism of IGF-I action remains
hypothetical, the present study provides evidence of
the anti¢brogenic e¡ect in vivo of IGF-I, at these
low doses. This anti¢brogenic e¡ect exerted by
IGF-I in the CCl4 model of liver cirrhosis seems to
be related to the antioxidant activities displayed by
this hormone.
Much evidence has been accumulated in recent
years supporting the hypothesis that oxidative stress
plays a major role in the pathogenesis of liver injury.
Fig. 4. Northern blot analysis: levels of collagen K1(III) mRNA in liver from healthy controls (CO, n = 12), untreated cirrhotic rats
(CI, n = 12) and the cirrhotic group treated with IGF-I (CI+IGF, n = 11). Expression of collagen K1(III) was 6.16-fold higher in the
CI group and 4.44-fold in the CI+IGF animals, than in the CO group. *P6 0.05, **P6 0.01.
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Although a causal relationship between oxidative
damage and hepatocellular injury still remains a mat-
ter of debate [37^42], in vitro experiments have dem-
onstrated that lipid peroxidation can cause cyto-
pathic changes and trigger gene transcription [37].
Lipid peroxidation seems to upregulate the expres-
sion and synthesis of ¢brogenic cytokines [44]. It
has been shown that lipid peroxidation products
stimulate the expression of collagen genes in myo¢-
broblasts [37,45] and the activity of hepatic prolyl
hydroxylase [38,43]. The activation of hepatic stellate
cells is mediated by oxidative stress [43]. Ito cells are
perisinusoidal cells thought to be a major source of
collagen in normal and ¢brotic livers [6]. These cells
(isolated in culture or in injured liver) assume a ¢-
broblast-like morphology expressing K-actin. These
transformed cells produce large amounts of procolla-
gen type I and also type III [6,47].
In the present study, a higher hepatic lipid peroxi-
dation, expression of collagen mRNAs, prolyl hy-
droxylase activity, and hydroxyproline content were
found in untreated cirrhotic rats as compared to cir-
rhotic animals treated with IGF-I. In addition, a
more extensive K-actin staining was present in the
livers from the untreated cirrhotic group.
The diminution of mRNA collagen was observed
in both collagen K1(I) and K1(III). In untreated cir-
rhotic animals the expression of collagen K1 type I
was 2.67 times higher than in the controls and it was
only 1.7 times that in treated cirrhotic animals. Col-
lagen K1 type I is the most important component of
extracellular matrix in the cirrhotic liver [6,46]. In
addition, the expression of collagen K1 type III was
6.16 times higher in untreated cirrhotic animals than
in controls and only 4.44 times higher in CI+IGF
rats.
Because prooxidant hepatocellular injury and re-
sulting ¢brogenesis occur in a diversity of human
liver diseases [9,11,46], and the mentioned previous
data indicated that IGF-I, at low doses, protects the
liver against oxidative damage [19], this antioxidant
mechanism of IGF-I could explain the anti¢brogenic
actions described in the present study. These ¢ndings
are in apparent opposition with the reported role of
IGF-I as a stimulator of Ito cell proliferation in vitro
[20^26] and with the observation of increased expres-
sion of IGF receptors during the process of ¢bro-
genesis [25].
A problem in interpreting these data is the re-
ported low expression of IGF-I receptors in hepato-
cytes that makes it di⁄cult to explain the biological
action of IGF-I in this tissue. However, there are
some data that may contribute to clarify this point.
Regenerating hepatocytes express IGF-I receptors
[50] and in addition we have recently observed a
reduction in GHR mRNA levels in the liver of cir-
rhotic rats and ^ interestingly ^ a higher expression
after IGF-I treatment [51]. Improved responses of
the liver parenchyma to GH could be behind the
e¡ects of IGF-I treatment [51].
On the other hand, several works have reported
that IGF-I induces hepatocyte growth factor
(HGF) production by liver cells [48]. Since HGF
may have important roles in liver regeneration and
induces anabolic e¡ects on cirrhotic liver [48,49], the
described bene¢cial actions of IGF-I could be sec-
ondary to HGF synthesis. In fact, transduction
with HGF gene suppressed the increase of transform-
ing growth factor-L1 (TGF-L1), which plays an es-
sential part in the progression of liver cirrhosis, in-
hibited ¢brogenesis and hepatocyte apoptosis, and
produced the complete resolution of ¢brosis in the
cirrhotic liver, thereby improving the survival rate of
rats with this severe illness [49]. The mechanism that
couples these two growth factors (HGF and IGF-I)
remains to be elucidated.
In summary, this study demonstrates that the ad-
ministration of IGF-I, at low doses, in vivo, not only
decreases hepatic collagen deposition but also its
production, acting as an anti¢brogenic agent at two
levels: decreasing prolyl hydroxylase activity and
mRNA expression of collagen. This work provides
new evidence of the bene¢cial e¡ect of IGF-I supple-
mentation in experimental liver cirrhosis. These re-
Fig. 5. Immunohistochemistry for K-actin in liver histologic sections (4 Wm). The immunostaining was focused around the vessel in
healthy controls (CO). More extensive zones were stained in untreated cirrhotic animals (CI), suggesting a major number of Ito cells
transformed into myo¢broblasts (P6 0.01 vs. CO). The stain for K-actin was signi¢cantly less in the cirrhotic group treated with
IGF-I (CI+IGF, P6 0.05 vs. CI group).
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sults provide an experimental basis for further stud-
ies aiming at exploring the potential of IGF-I in the
treatment of human cirrhosis.
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